Mainz Biomed Achieves Promising Results in Pancreatic Cancer Biomarker Study

Mainz Biomed N.V. has announced encouraging results from its feasibility study on a blood-based screening test for early pancreatic cancer detection. Conducted in collaboration with Liquid Biosciences, the study reported 100% sensitivity and 95% specificity in distinguishing between cancer patients and healthy individuals in a 30-subject cohort.

The panel of 18 proprietary biomarkers effectively identified cancer and precancerous lesions, potentially aiding early intervention. These top-line results affirm the test's robustness and set the stage for a larger confirmatory study.

Mainz Biomed plans to conduct further evaluations using Polymerase Chain Reaction technology with the goal of seeking FDA approval. This initiative forms part of the company's broader strategy to enhance diagnostic options for hard-to-detect cancers.